health
Novo Nordisk's Raised Forecast Fails to Change the Debate Over Its Obesity Business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
TL;DR
- Novo Nordisk reported a better-than-expected quarter and increased its full-year guidance.
- Analysts believe temporary factors boosted the quarter, and sales of obesity drugs were largely as anticipated, with the oral Wegovy slightly underperforming forecasts.
- Mixed clinical results for CagriSema have led to investor questions about Novo Nordisk's future pipeline.
- Eli Lilly's rival drugs, Zepbound and Mounjaro, have rapidly gained market share, intensifying competition.
- Novo Nordisk's stock has seen a significant decline from its peak, despite some recovery following the Wegovy pill launch.
- The CEO highlighted the Wegovy product portfolio as a key growth driver, particularly the rapid adoption of the Wegovy pill in the US.
- Novo Nordisk's American depositary receipts fell following the release of its quarterly report.